Frank Stonebanks MBA Venture Partner

Mr. Stonebanks has 23 years of executive operational and investment experience in biotech, pharma, med tech, drug delivery & healthcare IT across Canada, the US and globally.

Mr. Stonebanks is currently a Co-Founder and Managing General Partner of the BL Strategic Innovation Fund. Prior to that was the Founder, President / CEO and General Partner of Triphase LP, a novel biotech focused fund and operating company, where he raised $75 mm of non-dilutive cash, signed a $1.5 billion partnership with Celgene Corporation in a 3 product Option deal, and acquired 2 biopharma products in asset purchase and global licensing deals. On Nov. 16, 2016 Celgene announced the exercise of their 1st Option to acquire marizomib as part of the deal. Previously, Mr. Stonebanks served as the Chief Commercial Officer for the Ontario Institute for Cancer Research (OICR), where he was responsible for corporate partnering, managing their investment fund, and monetizing the institute’s intellectual property. He completed 7 equity and convertible debt investments, including 3 new co spin outs and one strategic sale of DVS to Fluidigm for $300 mm.

Previously, Mr. Stonebanks was President, CEO and Member of the Board of Directors of Cynvec, an early stage biotechnology firm spun out of New York University, where he developed the company’s positioning and strategy and led it through the investigational new drug process at the Food and Drug Administration in the U.S. He has also been a Senior Advisor, Healthcare and Life Sciences, for IBM, leading its global healthcare and life science mergers and acquisitions efforts and advising the company on its healthcare and life science strategy. Additionally he co-managed IBM’s $500 million venture fund. He was previously Vice-President Venture Investments at JJDC, Johnson & Johnson’s venture arm, and also Co-founder & CEO of The Macroflux® Corporation (now Zosano Pharma (Nasdaq: ZSAN), a Johnson & Johnson corporate spinoff of a drug/device platform, which had multiple products in Phase I and II studies. Mr. Stonebanks raised $90 mm in equity for the spin out. Prior to that Mr. Stonebanks was the head of Centocor / J&J’s global marketing groups in oncology and infectious diseases.

Frank completed his undergraduate degree in Exercise Physiology at the University of Victoria, B.C., Canada and his M.B.A. in Pharmaceutical Marketing at St. Joseph’s University in Philadelphia. Mr. Stonebanks also holds a diploma from the Amos Tuck School of Business Administration (Dartmouth) in Pharmaceutical Marketing.